Form 4: Teladoc Health Executive Carlos Nueno Reports Routine Stock Vesting and Tax-Related Share Sale

Teladoc Health's President, International, Carlos Nueno, reported the vesting of restricted and performance stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Carlos Nueno, President, International of Teladoc Health, Inc. (TDOC), reported transactions involving the company's common stock.
• On May 30, 2025, Mr. Nueno acquired a total of 8,712 shares of common stock through the vesting of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). This included 3,100 RSUs, 1,056 PSUs, and 4,556 RSUs.
• Following these acquisitions, Mr. Nueno's direct beneficial ownership of common stock increased to 21,603 shares before the subsequent sale.
• On June 2, 2025, Mr. Nueno disposed of 3,958 shares of common stock at a price of $6.86 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting of his performance stock unit and restricted stock unit awards.
• After all reported transactions, Mr. Nueno's direct beneficial ownership of Teladoc Health common stock stands at 17,645 shares.
• Remaining derivative securities include 9,302 Restricted Stock Units, 3,173 Performance Stock Units, and 31,894 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing is largely neutral, detailing routine executive compensation activities. The vesting of equity awards is a positive for executive retention and alignment, while the sale of shares is solely for tax purposes, which is a standard and expected practice, not indicating negative sentiment or a discretionary sale.

Positives

• The vesting of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) indicates the fulfillment of executive compensation plans, aligning management incentives with company performance.
• The acquisition of 8,712 shares through vesting demonstrates the company's commitment to its executive compensation structure.

Negatives

• A sale of 3,958 shares occurred, although it was specifically for tax withholding purposes, which is a common practice and not indicative of a discretionary sale.

Future Outlook

This Form 4 filing primarily reports past transactions related to executive compensation and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook, beyond the scheduled future vesting of equity awards.

Management Comments

• The transactions reflect the standard operation of the company's executive compensation program, where equity awards vest and a portion is sold to cover tax obligations.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. This specific filing reflects standard executive compensation practices within the healthcare technology industry, where equity awards like RSUs and PSUs are common tools for incentivizing and retaining key personnel. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The filing details routine executive compensation and tax-related share sales, which are common and generally do not have a direct material impact on the company's operational performance or strategic direction. It confirms the ongoing compensation structure for a key executive.
• Employees: The report highlights the standard equity compensation practices for executives, which can be a benchmark for broader employee incentive programs.

Next Steps

• The remaining portions of the 37,202 restricted stock units granted on March 3, 2023, will continue to vest in eight substantially equal quarterly installments after March 1, 2024.
• The remaining portions of the 12,679 performance stock units earned on March 1, 2024, will continue to vest in eight substantially equal quarterly installments thereafter.
• The remaining portions of the 54,675 restricted stock units granted on March 19, 2024, will vest in eight substantially equal quarterly installments beginning on June 1, 2025.

Key Dates

Recommendation

Keywords

Teladoc Health, TDOC, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Performance Stock Units, Executive Compensation, Share Sale, Tax Withholding, Carlos Nueno